Mechanisms, Characteristics, and Treatment of Neuropathic Pain and Peripheral Neuropathy Associated with Dinutuximab in Neuroblastoma Patients
Prognosis of metastatic neuroblastoma is very poor. Its treatment includes induction chemotherapy, surgery, high-dose chemotherapy, radiotherapy, and maintenance with retinoic acid, associated with the anti-GD2 monoclonal antibody (ch14.18) dinutuximab. Immunotherapy determined a significant improve...
Main Authors: | Stefano Mastrangelo, Serena Rivetti, Silvia Triarico, Alberto Romano, Giorgio Attinà, Palma Maurizi, Antonio Ruggiero |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-11-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/22/23/12648 |
Similar Items
-
Dinutuximab beta combined with chemotherapy in patients with relapsed or refractory neuroblastoma
by: Aleksandra Wieczorek, et al.
Published: (2023-02-01) -
Treatment of High-Risk Neuroblastoma with Dinutuximab and Chemotherapy Administered in all Cycles of Induction
by: Margaret Cupit-Link, et al.
Published: (2023-09-01) -
A Multi-Color Flow Cytometric Assay for Quantifying Dinutuximab Binding to Neuroblastoma Cells in Tumor, Bone Marrow, and Blood
by: Michelle E. Keyel, et al.
Published: (2023-09-01) -
Investigation of the Role of Dinutuximab Beta-Based Immunotherapy in the SIOPEN High-Risk Neuroblastoma 1 Trial (HR-NBL1)
by: Ruth Ladenstein, et al.
Published: (2020-01-01) -
Dinutuximab Beta in Children with High-Risk Neuroblastoma: Experience from a Single Center in Croatia
by: Jasminka Stepan Giljević, et al.
Published: (2022-06-01)